Latest Share Based Payments News

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

EMVision Medical Devices reported a $3.97 million loss for H1 2026, up 11% year-on-year, driven by increased share-based payments and expanded clinical activities. The company secured a $3 million government grant to advance stroke diagnosis in regional Australia.

Harmoney Corp Limited reported a striking 166% rise in Cash NPAT to $6.1 million for the half-year ended December 2025, driven by robust loan originations and improved interest margins. The company’s scalable model and refinancing efforts underpin its strong financial momentum.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Livium Ltd has turned a profit in the first half of FY26 despite lower revenues, supported by cost cuts and a new joint venture. The company also secured $4.5 million in fresh capital to expand its lithium-ion battery recycling and rare earth initiatives.

Energy Action Limited reported a 20.1% increase in revenue to $6.39 million for the half-year ended December 2025, driven by strong energy procurement growth. However, statutory profit after tax fell 35.7% to $593,881 amid rising expenses and amortisation.

BPH Energy Ltd reported a half-year net loss of $925,691, weighed down by investment write-downs and associate losses, while raising $1.2 million to fund exploration and development. The company’s future hinges on a Federal Court review of a critical offshore permit held by investee Advent Energy.

Asset Vision Co Limited reported a 27% increase in revenue to $3.06 million for the half-year ended December 2025, yet recorded a net loss of $54,052 due to deliberate investments in growth and product development.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

Forrestania Resources has secured 100% ownership of the Mt Palmer project and adjacent tenements, consolidating its position in Western Australia's Southern Cross and Mt Dimer gold hubs. The acquisition, settled through a substantial share issuance to Newcam Minerals, paves the way for accelerated development towards gold production.